European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. We aimed to develop a European evidence‐based consensus for the vaccination strategy of pwMS who are candidates for disease‐modifying therapies (DMTs).

[1]  O. Mirmosayyeb,et al.  Multiple sclerosis relapse after COVID-19 vaccination: A case report-based systematic review , 2022, Journal of Clinical Neuroscience.

[2]  H. Hartung,et al.  Vaccination and immunotherapies in neuroimmunological diseases , 2022, Nature Reviews Neurology.

[3]  M. Etemadifar,et al.  Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  C. Rapôso,et al.  SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab , 2022, medRxiv.

[5]  F. Leutmezer,et al.  B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients , 2022, Annals of neurology.

[6]  V. Di Lazzaro,et al.  Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies , 2021, Neurotherapeutics.

[7]  C. Agrati,et al.  Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies , 2021, Neurology.

[8]  T. Berger,et al.  T cells step up after SARS-CoV-2 vaccination with B cell depletion , 2021, Nature Reviews Neurology.

[9]  F. Lund-Johansen,et al.  Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  A. Achiron,et al.  Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study , 2021, Journal of Neuroimmunology.

[11]  C. Rapôso,et al.  Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. , 2021, JAMA neurology.

[12]  P. Bhargava,et al.  Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy , 2021, medRxiv.

[13]  V. Tomassini,et al.  mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[14]  G. Marfia,et al.  T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers , 2021, Multiple Sclerosis and Related Disorders.

[15]  M. Sá,et al.  Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations , 2021, Vaccines.

[16]  E. Wherry,et al.  Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. , 2021, medRxiv.

[17]  M. Cheung,et al.  Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients , 2021, Blood Advances.

[18]  A. Danek,et al.  First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine , 2021, Journal of Neurology.

[19]  L. Lix,et al.  Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study , 2021, CMAJ open.

[20]  N. Hahn.  Reader Response: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis: The VELOCE Study , 2021, Neurology.

[21]  C. Louapre,et al.  Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination? , 2021, Multiple sclerosis.

[22]  D. Centonze,et al.  Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus , 2021, Journal of Neurology.

[23]  A. Lascano,et al.  Rabies vaccination and multiple sclerosis relapse: A retrospective cohort study. , 2021, Multiple sclerosis and related disorders.

[24]  S. Bittner,et al.  Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets , 2021, Journal of central nervous system disease.

[25]  G. Comi,et al.  Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. , 2020, Multiple sclerosis.

[26]  A. Cross,et al.  Effects of MS disease-modifying therapies on responses to vaccinations: A review. , 2020, Multiple Sclerosis and Related Disorders.

[27]  M. Knight,et al.  Incidence, risk factors and impact of seasonal influenza in pregnancy: A national cohort study , 2020, medRxiv.

[28]  K. Schmierer,et al.  Protecting people with multiple sclerosis through vaccination , 2020, Practical Neurology.

[29]  M. Tintoré,et al.  Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. , 2020, Neurologia.

[30]  M. Tintoré,et al.  Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. , 2020, Neurologia.

[31]  A. Lascano,et al.  Risk of MS relapse after yellow fever vaccination , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[32]  Arindam Nandi,et al.  Why vaccines matter: understanding the broader health, economic, and child development benefits of routine vaccination , 2020, Human vaccines & immunotherapeutics.

[33]  K. Anja.  European Committee for Treatment and Research in Multiple Sclerosis , 2019, Kinder- und Jugendmedizin.

[34]  P. Calabresi,et al.  Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis , 2019, Proceedings of the National Academy of Sciences.

[35]  J. Sejvar,et al.  Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis , 2019, Neurology.

[36]  M. Dougados,et al.  2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.

[37]  M. Loeb,et al.  Pregnancy as a risk factor for severe influenza infection: an individual participant data meta-analysis , 2019, BMC Infectious Diseases.

[38]  M. Ramanathan,et al.  Epidemiology and treatment of multiple sclerosis in elderly populations , 2019, Nature Reviews Neurology.

[39]  C. Louapre,et al.  Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. , 2019, Revue neurologique.

[40]  P. Ljungman,et al.  Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). , 2019, The Lancet. Infectious diseases.

[41]  A. Bitton,et al.  Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary , 2019, Journal of the Canadian Association of Gastroenterology.

[42]  A. Winkelmann,et al.  Tick-borne encephalitis vaccination in multiple sclerosis , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[43]  M. Hecker,et al.  Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies , 2018, CNS neuroscience & therapeutics.

[44]  R. Sperling,et al.  Influenza Vaccination, Pregnancy Safety, and Risk of Early Pregnancy Loss. , 2018, Obstetrics and gynecology.

[45]  M. Burke.  Vaccinations for Older Adults , 2018, Current Geriatrics Reports.

[46]  H. Olberg,et al.  Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy , 2018, European journal of neurology.

[47]  S. Sheikh,et al.  Immune response to vaccines is maintained in patients treated with dimethyl fumarate , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[48]  E. Legangneux,et al.  Impact of siponimod on vaccination response in a randomized, placebo-controlled study , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[49]  Catherine Travis,et al.  Vaccines for Older Adults. , 2017, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[50]  S. Levin,et al.  Infectious Complications of Novel Multiple Sclerosis Therapies , 2017, Current Infectious Disease Reports.

[51]  C. Healy.  Pertussis vaccination in pregnancy , 2016, Human vaccines & immunotherapeutics.

[52]  Cody S. Olsen,et al.  Characteristics of Children and Adolescents With Multiple Sclerosis , 2016, Pediatrics.

[53]  Steven J Durning,et al.  Is There a Consensus on Consensus Methodology? Descriptions and Recommendations for Future Consensus Research , 2016, Academic medicine : journal of the Association of American Medical Colleges.

[54]  Mary P. Tully,et al.  How to use the nominal group and Delphi techniques , 2016, International Journal of Clinical Pharmacy.

[55]  Ashutosh Kumar Singh,et al.  Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis , 2015, Neurology.

[56]  A. Bar-Or,et al.  Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[57]  R. P. Heine,et al.  Vaccinations for Pregnant Women , 2015, Obstetrics and gynecology.

[58]  M. Sweetser,et al.  Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis , 2014, Journal of the Neurological Sciences.

[59]  A. Bousvaros,et al.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  H. Olberg,et al.  Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study , 2014, Multiple sclerosis.

[61]  C. Pozzilli,et al.  Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS , 2014, Neurology.

[62]  L. Kappos,et al.  Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy , 2013, PloS one.

[63]  A. Coles,et al.  Immune competence after alemtuzumab treatment of multiple sclerosis , 2013, Neurology.

[64]  A. Bar-Or,et al.  Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis , 2013, Neurology.

[65]  Sun-Whe Kim,et al.  Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab , 2013, European journal of neurology.

[66]  R. Schmouder,et al.  Pharmacodynamic Effects of Steady‐State Fingolimod on Antibody Response in Healthy Volunteers: A 4‐Week, Randomized, Placebo‐Controlled, Parallel‐Group, Multiple‐Dose Study , 2012, Journal of clinical pharmacology.

[67]  T. Walhart.  Parents, adolescents, children and the human papillomavirus vaccine: a review. , 2012, International nursing review.

[68]  A. Karni,et al.  Seasonal and H1N1v influenza vaccines in MS: Safety and compliance , 2012, Journal of the Neurological Sciences.

[69]  J. Correale,et al.  H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study , 2012, Multiple sclerosis.

[70]  H. Hartung,et al.  Vaccination against infection in patients with multiple sclerosis , 2012, Nature Reviews Neurology.

[71]  J. Correale,et al.  Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. , 2011, Archives of neurology.

[72]  J. Chataway,et al.  Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination , 2011, Journal of Neurology.

[73]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[74]  L. Samson.  Human papillomavirus vaccine for children and adolescents. , 2007, Paediatrics & child health.

[75]  G. Kochs,et al.  Protective Role of Beta Interferon in Host Defense against Influenza A Virus , 2006, Journal of Virology.

[76]  M. Lopez-Bresnahan,et al.  Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a , 2005, Neurology.

[77]  E. Salomonowitz,et al.  A controlled trial of tick-borne encephalitis vaccination in patients with multiple sclerosis. , 2003, Vaccine.

[78]  W. P. Mckinney.  Vaccines for international travel. , 2001, Primary care.

[79]  K. Toyka,et al.  Influenza vaccination in MS: Absence of T-cell response against white matter proteins , 2001 .

[80]  S Suissa,et al.  Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. , 2001, The New England journal of medicine.

[81]  C. Pozzilli,et al.  Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. , 1999, Neurology.

[82]  Aaron E. Miller,et al.  Influenza virus vaccination of patients with multiple sclerosis , 1997, Multiple sclerosis.

[83]  R. Knobler,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis , 1997, Neurology.

[84]  M. Cheang,et al.  Antibody response in seropositive multiple sclerosis patients vaccinated with attenuated live varicella zoster virus. , 1996, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[85]  C. Pozzilli,et al.  Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination , 1995, Journal of Neurology.

[86]  M. A. O. Ignacio,et al.  How to cite this article , 2016 .

[87]  C. Mazia.  Antigen-Specific Adaptive Immune Responses in Fingolimod-Treated Multiple Sclerosis Patients , 2011 .

[88]  S. Agarwal,et al.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. , 2010, Arthritis and rheumatism.